Subscribe
shutterstock_1396958186_pavel_kapysh
Pavel Kapysh / Shutterstock.com
1 March 2022Big PharmaMuireann Bolger

Arbutus, Genevant sue Moderna over COVID-19 vaccine tech

Arbutus Biopharma and Genevant Sciences are jointly suing Moderna over royalties from the sales of its COVID-19 vaccine, which allegedly uses their tech for a drug-delivery system without authorisation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Moderna hits Pfizer and BioNTech with COVID-19 vaccine patent suit
30 August 2022   Moderna has taken Pfizer and its German partner BioNTech to court, alleging that the pair copied Moderna’s technology when developing their COVID-19 vaccine.
Americas
US govt wades into Moderna COVID row
15 February 2023   The pharma company is accused of using patented tech for a drug-delivery system without authorisation | Moderna sought to escape the suit by claiming that its contract with the US government conferred immunity.
Americas
Moderna secures COVID-19 vaccine delivery win before appeals court
12 April 2023   Biotech fails to convince Federal Circuit to overturn PTAB finding | Invalidation of patent related to “Non-liposomal systems for nucleic acid delivery”.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Moderna hits Pfizer and BioNTech with COVID-19 vaccine patent suit
30 August 2022   Moderna has taken Pfizer and its German partner BioNTech to court, alleging that the pair copied Moderna’s technology when developing their COVID-19 vaccine.
Americas
US govt wades into Moderna COVID row
15 February 2023   The pharma company is accused of using patented tech for a drug-delivery system without authorisation | Moderna sought to escape the suit by claiming that its contract with the US government conferred immunity.
Americas
Moderna secures COVID-19 vaccine delivery win before appeals court
12 April 2023   Biotech fails to convince Federal Circuit to overturn PTAB finding | Invalidation of patent related to “Non-liposomal systems for nucleic acid delivery”.

More on this story

Americas
Moderna hits Pfizer and BioNTech with COVID-19 vaccine patent suit
30 August 2022   Moderna has taken Pfizer and its German partner BioNTech to court, alleging that the pair copied Moderna’s technology when developing their COVID-19 vaccine.
Americas
US govt wades into Moderna COVID row
15 February 2023   The pharma company is accused of using patented tech for a drug-delivery system without authorisation | Moderna sought to escape the suit by claiming that its contract with the US government conferred immunity.
Americas
Moderna secures COVID-19 vaccine delivery win before appeals court
12 April 2023   Biotech fails to convince Federal Circuit to overturn PTAB finding | Invalidation of patent related to “Non-liposomal systems for nucleic acid delivery”.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York